FAM84B was overexpressed in breast cancer [13], prostate cancer [15], esophageal squamous cell carcinoma (ESCC) [16, 17], epithelial ovarian cancer [18], and colorectal cancer [19], but significantly reduced in gastroesophageal junction adenocarcinomas [20]. Here, LRATD2 is linked to esophageal squamous cell carcinoma.